Objective To investigate the effects of different liver protective drugs on preventing liver injury induced by anti-tuberculosis drugs. Methods Retrospective analysis was made on 355 patients with primary pulmonary tuberculosis during intensified time. The patients received silibinon and bicyclol to prevent liver injury. 82 patients with TB were treated as control group during the same time. Results The number of patients with liver injury in silibinon group and bicyclol group were 16 cases (14.7%) and 55 cases (22.4%) respectively. The number of control group with liver injury was 9 cases (11.0%) (χ2 = 3.627,P > 0.05). The liver injuries within 4 weeks were mainly counted in. There is no difference between intervention and control groups(χ2 = 0.414,P > 0.05). There is no difference between three groups in liver injury degree (U = 0.288,P> 0.05). Conclusion Without high risk factors, anti-inflammatory and enzyme reduction drugs have no significant protective effects on liver injury caused by anti-tuberculosis drugs.%目的：探讨不同护肝药物预防抗结核药物所致肝损伤的作用。方法：回顾性分析355例肺结核患者在抗结核治疗强化期同时分别给予水飞蓟宾胶囊（水飞蓟宾组）及双环醇片（双环醇组）预防药物性肝损伤作用，并选取同期抗结核治疗82例肺结核患者作为对照组。结果：水飞蓟宾组和双环醇组出现肝损伤分别为16例（14．7％）和55例（22．4％）；对照组肝功能损伤为9例（11．0％）（χ2＝3．627，P＞0．05）；肝损伤出现时间均以4周内为主，各组无明显差异（χ2＝0．414，P＞0．05）；三组肝损伤程度比较无明显差异（U＝0．288，P＞0．05）。结论：在无高危因素情况下，采用抗炎保肝药和降酶药预防抗结核药物所致肝损伤疗效不确切。
展开▼
